Comparative Pharmacology
Head-to-head clinical analysis: MYCELEX G versus SPECTAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCELEX G versus SPECTAZOLE.
MYCELEX-G vs SPECTAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing cell membrane permeability.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily for 7 days or 200 mg once daily for 3 days; or 500 mg single dose. Also available as 1% vaginal cream, 1 applicatorful (5 g) intravaginally once daily for 7-14 days.
Apply a thin layer to affected area once daily for 4-4 weeks; duration depends on indication.
None Documented
None Documented
Biphasic: initial half-life ~30 minutes, terminal half-life ~30 hours; clinical significance: supports once-daily dosing for topical/vaginal formulations.
Terminal elimination half-life is approximately 24-30 hours in patients with normal renal function, allowing once-daily dosing.
Primarily hepatic metabolism; about 80-90% of dose excreted as metabolites in feces via biliary excretion, less than 1% unchanged in urine.
Primarily renal: approximately 70% of an oral dose is excreted unchanged in urine; biliary/fecal excretion accounts for ~20%, with the remainder as metabolites.
Category C
Category C
Antifungal
Antifungal